Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

Aziza T. Shad; Jeffrey S. Huo; Courtney Darcy; Amal Abu-Ghosh; Giuseppe Esposito; Mary Jo Holuba; Nancy Robey; Kenneth R. Cooke; Heather J. Symons; Allen R. Chen; Nicolas J. Llosa

doi:10.1002/pbc.26257

Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

Aziza T. Shad, Jeffrey S. Huo, Courtney Darcy, Amal Abu-Ghosh, Giuseppe Esposito, Mary Jo Holuba, Nancy Robey, Kenneth R. Cooke, Heather J. Symons, Allen R. Chen, Nicolas J. Llosa

School of Medicine

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.

Original language	English (US)
Article number	e26257
Journal	Pediatric Blood and Cancer
Volume	64
Issue number	3
DOIs	https://doi.org/10.1002/pbc.26257
State	Published - Mar 1 2017

Keywords

Hodgkin lymphoma
anti-PD1
haploidentical bone marrow transplant
immunotherapy
nivolumab
relapse

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26257

Cite this

Shad, A. T., Huo, J. S., Darcy, C., Abu-Ghosh, A., Esposito, G., Holuba, M. J., Robey, N., Cooke, K. R., Symons, H. J., Chen, A. R., & Llosa, N. J. (2017). Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report. Pediatric Blood and Cancer, 64(3), Article e26257. https://doi.org/10.1002/pbc.26257

@article{f1ffb49ffb19452899a6b9f0a95ab3d4,

title = "Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report",

abstract = "To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.",

keywords = "Hodgkin lymphoma, anti-PD1, haploidentical bone marrow transplant, immunotherapy, nivolumab, relapse",

author = "Shad, {Aziza T.} and Huo, {Jeffrey S.} and Courtney Darcy and Amal Abu-Ghosh and Giuseppe Esposito and Holuba, {Mary Jo} and Nancy Robey and Cooke, {Kenneth R.} and Symons, {Heather J.} and Chen, {Allen R.} and Llosa, {Nicolas J.}",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2017",

month = mar,

day = "1",

doi = "10.1002/pbc.26257",

language = "English (US)",

volume = "64",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation

T2 - A case report

AU - Shad, Aziza T.

AU - Huo, Jeffrey S.

AU - Darcy, Courtney

AU - Abu-Ghosh, Amal

AU - Esposito, Giuseppe

AU - Holuba, Mary Jo

AU - Robey, Nancy

AU - Cooke, Kenneth R.

AU - Symons, Heather J.

AU - Chen, Allen R.

AU - Llosa, Nicolas J.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.

AB - To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.

KW - Hodgkin lymphoma

KW - anti-PD1

KW - haploidentical bone marrow transplant

KW - immunotherapy

KW - nivolumab

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=84988412553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988412553&partnerID=8YFLogxK

U2 - 10.1002/pbc.26257

DO - 10.1002/pbc.26257

M3 - Article

C2 - 27650634

AN - SCOPUS:84988412553

SN - 1545-5009

VL - 64

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 3

M1 - e26257

ER -

Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this